RP2 with nivolumab for untreated uveal melanoma
Treatments studied
Part of Cancer, Eyes & vision, Skin clinical trials.
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have uveal melanoma that has spread (metastatic) and cannot be fully removed with surgery.
- You have at least one tumor that is at least 1 cm (about the size of a pea) that can be injected directly with the study drug.
- You are willing to give a small sample of your tumor (biopsy) for testing.
- You have not had any immunotherapy (checkpoint inhibitors) since your uveal melanoma diagnosis.
- You do not have active infections like hepatitis B, C, HIV, or serious herpes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of an investigational viral therapy (VO) and the immunotherapy nivolumab for people with advanced melanoma that has stopped responding to previous anti-PD-1 and anti-CTLA-4 treatments. The goal is to see if this combination works better than other standard treatments your doctor might choose.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This trial is testing a combination of two oral medications (darovasertib and crizotinib) after standard local treatment for high-risk uveal melanoma that has not spread. The goal is to see if this treatment can reduce the risk of the cancer coming back.
This trial tests a new kind of virus-based treatment (RP1) given directly into melanoma tumors to see if it can reduce the chance of cancer spreading to nearby lymph nodes. It's for people with thicker or more advanced skin melanoma that still has visible tumor or positive margins after biopsy.
This Phase 2 trial studies whether RP2, added to standard second-line treatment, can improve outcomes for people with advanced liver cancer or bile duct/gallbladder cancer. It may help by training the immune system to better attack the cancer after the cancer has already grown despite prior treatment.
This trial tests a new drug (RBP-01) given before standard treatment for uveal melanoma, a type of eye cancer. The goal is to see if the drug can shrink the tumor or improve outcomes for people who need eye removal or high-risk radiation therapy.
Hear when a new Metastatic Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.